Blood tests for clot risk in immune thrombocytopenia
Part of Heart & circulation clinical trials.
This study looks at whether certain antibodies and small particles in your blood can help doctors identify patients with ITP who are at risk for blood clots. It aims to improve diagnosis and prevention of clotting issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with primary chronic immune thrombocytopenia (ITP).
- You must be 18 years old or older.
- Your low platelet count must not be caused by another condition like pregnancy, high blood pressure, heart disease, or liver/kidney problems.
- You must not have antiphospholipid syndrome (APS).
- You may or may not have had a blood clot (thrombosis) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
This study helps doctors better understand immune thrombocytopenia (ITP) by collecting basic patient information and, if you agree, storing blood samples. It may help future care decisions and research for people with ITP.
Hear when a new Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.